ArticleCancer discovery2020
Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 58 citations in OpenAlex.
- A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma.Cancer discovery · 2022Trial
- Spatial single cell transcriptomic analysis informs tumor developmental hierarchy of DICER1 syndrome related sarcoma.Nature communications · 2026Article
- p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy.Cancer discovery · 2026Article
- MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer.Cancer research · 2025Article
- Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations.Cancer discovery · 2025Article
- Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer.Prostate cancer and prostatic diseases · 2025Article
- ATAD2 Drives Prostate Cancer Progression to Metastasis.Molecular cancer research : MCR · 2025Article
- In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy.Cancer cell · 2024Article
- Condensate-Promoting ENL Mutation Drives Tumorigenesis In Vivo Through Dynamic Regulation of Histone Modifications and Gene Expression.Cancer discovery · 2024Article
- Down-regulation of SLC14A1 in prostate cancer activates CDK1/CCNB1 and mTOR pathways and promotes tumor progression.Scientific reports · 2024Article
- Rare histologic transformation of a CTNNB1 (β-catenin) mutated prostate cancer with aggressive clinical course.Diagnostic pathology · 2024Article
- How CRISPR Is Revolutionizing the Generation of New Models for Cancer Research.Cold Spring Harbor perspectives in medicine · 2024Review
- Advances in Making Cancer Mouse Models More Accessible and Informative through Non-Germline Genetic Engineering.Cold Spring Harbor perspectives in medicine · 2024Review
- Generation of precision preclinical cancer models using regulated in vivo base editing.Nature biotechnology · 2024Article
- Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease.Nature cancer · 2024Article
- Molecular imaging reveals the heterogeneous progression of tumor cells and tumor stroma: a practice of FDG PET and FAPI PET in diagnosing PSMA-negative bone metastases of progressive prostate cancer.American journal of nuclear medicine and molecular imaging · 2024Article
- Wnt Signaling and Therapeutic Resistance in Castration-Resistant Prostate Cancer.Current pharmacology reports · 2023Article
- Development and validation of a tumor immune cell infiltration-related gene signature for recurrence prediction by weighted gene co-expression network analysis in prostate cancer.Frontiers in genetics · 2023Article
- Review
- In Vivo Models for Prostate Cancer Research.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 4 institutions in 1 country.
Josef Leibold *Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York.
Marcus Ruscetti *Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-4394-2087
Zhen Cao *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Yu-Jui HoDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York.
Timour BaslanDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York.
Min ZouDepartments of Pharmacology, Urology, Medicine, Pathology and Cell Biology, and Systems Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.
Wassim AbidaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Judith FeuchtCenter for Cell Engineering and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Teng HanWeill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, New York.
Francisco M BarrigaDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York.
Kaloyan M TsanovDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0001-9007-4844
Leah ZamechekDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0003-2863-2950
Amanda KulickDepartment of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Corina AmorDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York.
Sha TianDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York.
Katarzyna RybczykDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York.
Nelson R SalgadoDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0003-2056-341X
Francisco J Sánchez-RiveraDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-8466-8563
Philip A WatsonHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Elisa de StanchinaDepartment of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
John E WilkinsonDepartment of Pathology, University of Michigan, Ann Arbor, Michigan.
Lukas E DowSandra and Edward Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, New York.ORCID https://orcid.org/0000-0001-7048-1418
Cory Abate-ShenDepartments of Pharmacology, Urology, Medicine, Pathology and Cell Biology, and Systems Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.
Charles L SawyersHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. lowes@mskcc.org sawyersc@mskcc.org.ORCID https://orcid.org/0000-0003-4955-6475
Scott W LoweDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York. lowes@mskcc.org sawyersc@mskcc.org.ORCID https://orcid.org/0000-0002-5284-9650
Memorial Sloan Kettering Cancer Center · USColumbia University Irving Medical Center · USCornell University · USUniversity of Michigan · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0MScientific ReagentsP01CA087497 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI PRIVES, CAROL, STOCKWELL, BRENT R. · 2000 to 2021
$35.4MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9MThe MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2017 to 2021
$6.8MPreclinical analyses of advanced prostate cancer in genetically-engineered miceR01CA173481 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Cory Abate-Shen · 2013 to 2026
$6.1MRole of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7MMolecular mechanisms of prostate cancer metastasisR01CA183929 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABATE-SHEN, CORY · 2015 to 2025
$4.1MUnderstanding Resistance to Next Generation AntiandrogensR01CA155169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2012 to 2022
$3.8MRapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignanciesR01CA233944 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W. · 2020 to 2024
$2.4MTranslational Research in Oncology Training ProgramT32CA160001 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2011 to 2020
$2.0MSenescence-Associated Secretory Phenotype (SASP) modulation of the tumor microenvironment as a therapeutic strategy for KRAS-driven tumorsK99CA241110 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI RUSCETTI, MARCUS A. · 2019 to 2019
$137kHoward Hughes Medical InstituteNCI NIH HHS K99 CA241110NCI NIH HHS P01 CA087497NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS R01 CA155169NCI NIH HHS R01 CA173481NCI NIH HHS R01 CA183929NCI NIH HHS R01 CA193837NCI NIH HHS R01 CA233944NCI NIH HHS T32 CA160001NCI NIH HHS U54 CA224079NIH HHS U54 OD020355
Abstract
To study genetic factors influencing the progression and therapeutic responses of advanced prostate cancer, we developed a fast and flexible system that introduces genetic alterations relevant to human disease directly into the prostate glands of mice using tissue electroporation. These electroporation-based genetically engineered mouse models (EPO-GEMM) recapitulate features of traditional germline models and, by modeling genetic factors linked to late-stage human disease, can produce tumors that are metastatic and castration-resistant. A subset of tumors with
Indexed as
AnimalsDisease Models, AnimalHumansMaleMiceNeoplasm MetastasisProstatic NeoplasmsTissue EngineeringWnt Signaling Pathway
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.